In addition, at least 10 of the roughly 70 approved kinase inhibitors used for the treatment of cancer have even been shown to activate PXR [13,15,63,64,65,67] (Supplementary Table S2), which may result in autoinduction of drug metabolism and elimination. Here, NR1I2 is linked to cancer.